Key result
Antihypertensives reducing glomerular capillary pressure ameliorate experimental glomerular disease and prevent hemodynamic injury.
Reducing glomerular capillary pressure through systemic hypertension treatment is critical to preventing hemodynamic injury in renal disease.
Answers are grounded in this paper and cite their sources.
Supports intraglomerular pressure reduction experimentally; leaves open translation to human CKD progression.
Experimental data are summarized that provide evidence that enhanced transmission of systemic hypertension to the glomerulus occurs in the setting of reduced renal mass. It is proposed that similar adaptive glomerular hemodynamic alterations occur in parenchymal renal disease in humans, favoring the development of intraorgan hypertension. Accelerated vascular and glomerular damage and functional deterioration result. Treatment of systemic hypertension with agents that reduce glomerular capillary pressure has been shown to ameliorate the manifestations of experimental glomerular disease. The importance of preventing hemodynamic injury to the arterioles and glomerular capillaries in the management of human renal disease is stressed.
No takes yet. Share an insight, caveat, or question.
Baldwin et al. (1987) conducted a review in Hypertension and Renal Diseases. Agents that reduce glomerular capillary pressure was evaluated. Treatment of systemic hypertension with agents that reduce glomerular capillary pressure ameliorates manifestations of experimental glomerular disease and prevents hemodynamic injury.
Synapse has enriched 10 related papers. Consider them for comparative context: